BioStock: Abliva has strengthened its position during 2020

For Abliva, the first half of the year has meant a continuation of the process that began in autumn 2019, when the company decided to focus its work on primary mitochondrial diseases. In 2020, its position has also been strengthened through a rights issue and the addition of well-regarded life science investor Hadean Ventures to the owner list. BioStock contacted CEO Erik Kinnman to hear more about the past six months and what he expects from the rest of 2020.

Read the full interview at biostock.se:

https://www.biostock.se/en/abliva-has-strengthened-its-position-during-2020/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Subscribe

Documents & Links

Quick facts

BioStock: Abliva has strengthened its position during 2020
Tweet this